ANTIBODY RAISED AGAINST TO HUMAN GASTROENTERIC TRACT EPITHELIAL TUMOR ANTIGEN RELATED WITH ALPHA-6,BETA-4-INTEGRIN Russian patent published in 2005 - IPC

Abstract RU 2266298 C2

FIELD: medicine, oncology, gastroenterology, immunobiotechnology.

SUBSTANCE: invention describes an antibody or its derivative, or its fragment showing the structure able to bind the target structure. Antibody is located inside and on surface of human gastroenteric tract epithelial tumor cells and in subpopulation of normal gastroenteric tract epithelial cells. Indicated binding structures comprise sequences determining the complementarity of the region (CDR) in light chain comprising in main amino acids at number 23-33 (CDR 1), 49-55 (CDR 2), 88-98 (CDR 3) of amino acid sequence represented in SEQ ID NO:2, and CDR sequence in heavy chains comprising in main amino acids at number 158-162 (CDR 1), 177-193 (CDR 2), 226-238 (CDR 3) of amino acid sequence represented in SEQ ID NO:2, or other binding structures with similar unique binding properties. Also, invention describes the target-structure located inside or on surface of tumor cells: vaccine composition designated for treatment of malignant disease in human and comprising abovementioned antibody. Also, invention describes methods for treatment and diagnosis of malignant disease. Using this invention provides preparing antibodies that relieve identification of new phenotype-specific tumor-associated antigens, to predict and treat metastatic human diseases. Invention can be used in medicinal practice.

EFFECT: valuable medicinal properties of antibodies.

37 cl, 21 dwg, 4 tbl, 8 ex

Similar patents RU2266298C2

Title Year Author Number
NEW ANTIBODY SHOWING SPECIFICITY TO MALIGNANT LARGE INTESTINE TUMOR 2001
  • Brodin Tomas N.
  • Karl'Strem Pia J.
  • Nil'Son Bo Kh. K.
  • Ol'Sson Lennart G.
  • Tordsson M. Esper
RU2268068C2
CONJUGATE ELICITING ABILITY TO ACTIVATE IMMUNE SYSTEM AND PHARMACEUTICAL COMPOSITION COMPRISING INDICATED CONJUGATE 1997
  • Antonsson Per
  • Khansson Jokhan
  • B'Erk Per
  • Dol'Sten Mikaehl'
  • Kalland Ter'E
  • Abramsen Lars
  • Forsberg Jeran
RU2198895C2
CONJUGATE TO STIMULATE IMMUNE RESPONSE AGAINST A TARGET CELL, METHOD TO TREAT MALIGNANT TUMORS IN MAMMALIANS 1995
  • Abrakhmsen Lars
  • B'Erk Per
  • Dokhlsten Mikaehl'
  • Kalland Ter'E
RU2183215C2
BIOLOGICAL MATERIALS AND APPLICATION THEREOF 2006
  • Frendeus Bjorn
  • Karlsson Roland
RU2432363C9
HUMANIZED ANTI-VEGF MONOCLONAL ANTIBODY 2020
  • Shie Lianzy
  • San Chanyun
  • Vang Rui
  • Chzhan Ksyao
RU2809746C2
NOVEL ANTIBODIES 2008
  • Ljan Vehj-Chin
  • Plauman Gregori D.
  • U Jan'
  • E Vehjlan'
RU2490277C2
CANCER-MODIFYING ANTIBODIES 2008
  • Jang Dejvid S.F.
  • Findlej Khelen P.
  • Khan S'Jusan Eh.
  • Popp Lajza A.
RU2468036C2
USE OF CD 151 ANTIBODIES FOR TREATING CANCER 2007
  • Ajuv Zhan-Fransua
  • Getsh Lilian
RU2464041C2
INHIBITION OF TUMOUR METASTASES BY ANTIBODIES AGAINST NEUROPILINE-2 2007
  • U Jan'
  • Ljan Vehj-Chin
  • Uotts Rajan Dzhefferson
  • Bagri Anil Durgadas
RU2437677C2
SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMEL SINGLE-CHAIN ANTIBODIES, AIMED ON TUMOR RECEPTORS CD47/CD44, INTENDED FOR THERAPY OF MALIGNANT NEOPLASMS 2016
  • Chumakov Stepan Petrovich
  • Kravchenko Yuliya Evgenevna
  • Ratnikova Natalya Mikhajlovna
  • Frolova Elena Ivanovna
RU2658764C1

RU 2 266 298 C2

Authors

Brodin Tomas N.

Karlstrem Pia J.

Ol'Sson Lennart G.

Tordsson M. Jesper

Kerni Fillip P.

Nil'Son Bo Kh.K.

Dates

2005-12-20Published

2000-10-26Filed